Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

This article was originally published in The Pink Sheet Daily

Executive Summary

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

You may also be interested in...



From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve

In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services

Creative Funding Options For China; Investors Battle Perception of Home Court Advantage

The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?

SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel